

March 28, 2019



## Oragenics, Inc. to Present at Spring Investor Summit on April 1, 2019

TAMPA, Fla.--(BUSINESS WIRE)-- Oragenics, Inc. (NYSE American: OGEN), a leader in the development of new antibiotics against infectious diseases and effective treatments for oral mucositis (OM), today announced it will present and meet with investors at Spring Investor Summit on April 1, 2019 at 1:00 PM ET as part of Track 1 at The Essex House in New York City.

Interested investors may request a one-on-one meeting at Spring Investor Summit by registering for the meeting at [www.microcapconf.com](http://www.microcapconf.com), or contacting conference administrators at [info@microcapconf.com](mailto:info@microcapconf.com).

### About Oragenics, Inc.

We are focused on becoming a leader in novel antibiotics against infectious disease and on developing effective treatments for oral mucositis. Oragenics, Inc. has established two exclusive worldwide channel collaborations with Intrexon Corporation and its subsidiaries. The collaborations allow Oragenics to accelerate the development of much needed new antibiotics that can work against resistant strains of bacteria and the development of biotherapeutics for oral mucositis and other diseases and conditions of the oral cavity, throat, and esophagus.

For more information about Oragenics, please visit [www.oragenics.com](http://www.oragenics.com).

**Safe Harbor Statement:** Under the Private Securities Litigation Reform Act of 1995: This release includes forward-looking statements that reflect management's current views with respect to future events and performance. These forward-looking statements are based on management's beliefs and assumptions and information currently available. The words "believe," "expect," "anticipate," "intend," "estimate," "project" and similar expressions that do not relate solely to historical matters identify forward-looking statements. Investors should be cautious in relying on forward-looking statements because they are subject to a variety of risks, uncertainties, and other factors that could cause actual results to differ materially from those expressed in any such forward-looking statements. These factors include, but are not limited to, risks and uncertainties described in our filings with the U.S. Securities and Exchange Commission. Oragenics assumes no responsibility to update any forward-looking statements contained in this press release or with respect to the matters described herein.

View source version on businesswire.com: <https://www.businesswire.com/news/home/20190328005066/en/>

### Oragenics, Inc.

Corporate:

Michael Sullivan, 813-286-7900

Chief Financial Officer

[msullivan@oragenics.com](mailto:msullivan@oragenics.com)

or

### Investors:

John Marco

Managing Director

CORE IR

310-819-2948

[johnm@coreir.com](mailto:johnm@coreir.com)

### Media:

Jules Abraham

CORE IR

917-885-7378

[julesa@coreir.com](mailto:julesa@coreir.com)

Source: Oragenics, Inc.

